Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy

Background Blocking of the Tumor Necrosis Factor (TNF) activity is a successful therapeutic approach for 50-60% of rheumatoid arthritis (RA) patients. However, there are yet no biomarkers to stratify patients for anti-TNF therapy. Rheumatoid factor (RF) and anti-cyclic-citrullinated antibodies (anti...

Descripción completa

Detalles Bibliográficos
Autores: Julia, A, Lopez-Lasanta, M, Blanco, F, Gomez, A, Haro, I, Mas, AJ, Erra, A, Vivar, MLG, Monfort, J, Sanchez-Fernandez, S, Gonzalez, I, Alperi, M, Castellanos-Moreira, R, Fernandez-Nebro, A, Diaz-Torne, C, Palau, N, Lastra, R, Llados, J, Sanmarti, R, Marsal, S
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p4802
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4802
https://ddd.uab.cat/record/271995
Access Level:acceso abierto
Palabra clave:Rheumatoid arthritis
Treatment response
Anti-TNF therapy
Autoantibodies
id ES_3c625f0ea386d6bb8dc51d55ea2d1fdc
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p4802
network_acronym_str ES
network_name_str España
repository_id_str
spelling Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapyJulia, ALopez-Lasanta, MBlanco, FGomez, AHaro, IMas, AJErra, AVivar, MLGMonfort, JSanchez-Fernandez, SGonzalez, IAlperi, MCastellanos-Moreira, RFernandez-Nebro, ADiaz-Torne, CPalau, NLastra, RLlados, JSanmarti, RMarsal, SRheumatoid arthritisTreatment responseAnti-TNF therapyAutoantibodiesBackground Blocking of the Tumor Necrosis Factor (TNF) activity is a successful therapeutic approach for 50-60% of rheumatoid arthritis (RA) patients. However, there are yet no biomarkers to stratify patients for anti-TNF therapy. Rheumatoid factor (RF) and anti-cyclic-citrullinated antibodies (anti-CCP) have been evaluated as biomarkers of response but the results have shown limited consistency. Anti-carbamylated protein (anti-CarP) and anti-peptidylarginine deiminase type 4 (anti-PAD4) antibodies have been much less studied. Despite being linked to common immune processes, the interaction between these markers has not been evaluated yet. Our aim was to analyze the interaction between these four antibodies in relation to the response to anti-TNF therapy. Methods For this objective, a prospective cohort of n = 80 RA patients starting anti-TNF therapy was recruited. Serum determinations at baseline were performed for RF, anti-CCP, anti-CarP and anti-PAD4 antibodies using enzyme-linked immunosorbent assays (ELISA). The clinical response to anti-TNF therapy was determined at week 12 using the change in DAS28 score. Association was performed using multivariate linear regression adjusting for baseline DAS28, sex and age. Results The interaction between pairs of antibodies was tested by the addition of an interaction term. We found two highly significant antibody interactions associated with treatment response: anti-CarP with anti-PAD4 (p = 0.0062), and anti-CCP with RF (p = 0.00068). The latter antibody interaction was replicated in an independent retrospective cohort of RA patients (n = 199, p = 0.04). Conclusions The results of this study suggest that antibody interaction effects are important factors in the response to anti-TNF therapy in RA.BMC2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4802https://ddd.uab.cat/record/271995BMC MUSCULOSKELETAL DISORDERSISSN: 14712474reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p48022026-06-14T12:41:47Z
dc.title.none.fl_str_mv Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy
title Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy
spellingShingle Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy
Julia, A
Rheumatoid arthritis
Treatment response
Anti-TNF therapy
Autoantibodies
title_short Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy
title_full Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy
title_fullStr Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy
title_full_unstemmed Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy
title_sort Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy
dc.creator.none.fl_str_mv Julia, A
Lopez-Lasanta, M
Blanco, F
Gomez, A
Haro, I
Mas, AJ
Erra, A
Vivar, MLG
Monfort, J
Sanchez-Fernandez, S
Gonzalez, I
Alperi, M
Castellanos-Moreira, R
Fernandez-Nebro, A
Diaz-Torne, C
Palau, N
Lastra, R
Llados, J
Sanmarti, R
Marsal, S
author Julia, A
author_facet Julia, A
Lopez-Lasanta, M
Blanco, F
Gomez, A
Haro, I
Mas, AJ
Erra, A
Vivar, MLG
Monfort, J
Sanchez-Fernandez, S
Gonzalez, I
Alperi, M
Castellanos-Moreira, R
Fernandez-Nebro, A
Diaz-Torne, C
Palau, N
Lastra, R
Llados, J
Sanmarti, R
Marsal, S
author_role author
author2 Lopez-Lasanta, M
Blanco, F
Gomez, A
Haro, I
Mas, AJ
Erra, A
Vivar, MLG
Monfort, J
Sanchez-Fernandez, S
Gonzalez, I
Alperi, M
Castellanos-Moreira, R
Fernandez-Nebro, A
Diaz-Torne, C
Palau, N
Lastra, R
Llados, J
Sanmarti, R
Marsal, S
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Rheumatoid arthritis
Treatment response
Anti-TNF therapy
Autoantibodies
topic Rheumatoid arthritis
Treatment response
Anti-TNF therapy
Autoantibodies
description Background Blocking of the Tumor Necrosis Factor (TNF) activity is a successful therapeutic approach for 50-60% of rheumatoid arthritis (RA) patients. However, there are yet no biomarkers to stratify patients for anti-TNF therapy. Rheumatoid factor (RF) and anti-cyclic-citrullinated antibodies (anti-CCP) have been evaluated as biomarkers of response but the results have shown limited consistency. Anti-carbamylated protein (anti-CarP) and anti-peptidylarginine deiminase type 4 (anti-PAD4) antibodies have been much less studied. Despite being linked to common immune processes, the interaction between these markers has not been evaluated yet. Our aim was to analyze the interaction between these four antibodies in relation to the response to anti-TNF therapy. Methods For this objective, a prospective cohort of n = 80 RA patients starting anti-TNF therapy was recruited. Serum determinations at baseline were performed for RF, anti-CCP, anti-CarP and anti-PAD4 antibodies using enzyme-linked immunosorbent assays (ELISA). The clinical response to anti-TNF therapy was determined at week 12 using the change in DAS28 score. Association was performed using multivariate linear regression adjusting for baseline DAS28, sex and age. Results The interaction between pairs of antibodies was tested by the addition of an interaction term. We found two highly significant antibody interactions associated with treatment response: anti-CarP with anti-PAD4 (p = 0.0062), and anti-CCP with RF (p = 0.00068). The latter antibody interaction was replicated in an independent retrospective cohort of RA patients (n = 199, p = 0.04). Conclusions The results of this study suggest that antibody interaction effects are important factors in the response to anti-TNF therapy in RA.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4802
https://ddd.uab.cat/record/271995
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4802
https://ddd.uab.cat/record/271995
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv BMC
publisher.none.fl_str_mv BMC
dc.source.none.fl_str_mv BMC MUSCULOSKELETAL DISORDERS
ISSN: 14712474
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869406365697441792
score 15,811543

Similares en LA Referencia